What is ReNeuron Group plc (RNUGF)?

ReNeuron Group plc (RNUGF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of RNUGF?

The current price of RNUGF is $0.00. Prices are updated in real time on Stocks360.

What is RNUGF's price-to-earnings (PE) ratio?

RNUGF's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is RNUGF's market capitalization?

RNUGF's market capitalization is $62,891.00, placing it in the small-cap tier.

ReNeuron Group plc (RNUGF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$62.89K

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.04

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

500.00

ReNeuron Group plc (RNUGF) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $62.89K. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $0.00 2026-10-26 · $0.00 (+0.00%)

Earnings

Most Recent

Mar 31, 2022

EPS $-0.10 vs est. $-0.15

Beat by $0.05

Next Earnings

Nov 11, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About ReNeuron Group plc

ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage. The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.09×
P/B	0.01×
P/FCF (TTM)	-0.01×
EV / EBITDA	0.89×
EV / Sales	-10.73×
Earnings Yield	-11534.27%
Free Cash Flow Yield	-16417.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$5.69M
Net Income (TTM)	-$5.41M
Free Cash Flow (TTM)	-$7.69M
Net Debt	-$5.73M
Working Capital	$4.52M
Gross Margin	-742.08%
Operating Margin	-1342.45%
Net Margin	-1020.38%
Return on Equity	-72.37%
Return on Invested Capital	-105.51%